Prevention Of Nephrotoxicity Following Bone Marrow Transplantation Using Urodilatin and Mannitol
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to combine Urodilatin (ANP analogue), which will increase
glomerular filtration rate (GFR), and mannitol, which will increase the rate of urinary flow
and solute excretion. We intend to treat twenty consecutive allogeneic bone marrow transplant
patients in a phase II study comparing results with historical controls.
We hypothesize that the incidence of renal dysfunction, ARF and thus mortality in allogeneic
bone marrow transplantation can be significantly reduced by the use of protective agents
Urodilatin and mannitol. We feel that this combination is best administered prior to and
during the first two weeks of treatment when patients encounter immunosuppressive agents and
the onset of early transplantation complications.